"As innovator companies’ R&D pipelines are shifting towards biologics, generic companies are following suit. Small molecules are also important, but biologics can add greater value "
~G V Prasad
- Log in to post comments
- 189 views
Publish Date
Article Content
Home Page Card Image
Deep Dive Comments